IPF Management and Antifibrotic Therapy

Released On
January 28, 2022

Expires On
November 28, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Critical Care, Pulmonology, Primary Care

Topic(s)
Pulmonary Fibrosis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The France Foundation.

 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™, maximum of 1.0 ABIM medical knowledge MOC points

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of pulmonologists, internists, primary care providers, and other health care providers who manage patients with ILD.

Program Overview

This activity will cover patient adherence, treatment switching, and care coordination with community healthcare providers for patients with IPF.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the importance of, and challenges associated with, adherence to antifibrotic therapy
  • Discuss when to stop or switch antifibrotic therapy when necessary
  • Explain how to involve primary care providers, advanced practice providers, nurses, and therapists in coordination of care of patients with IPF from the standpoint of diagnosis, treatment, management of comorbidities, and optimization of patient well-being

Faculty

FACULTY_NAME

Kevin Flaherty, MD

Professor, Critical Care Medicine, Internal Medicine, Pulmonary Diseases
University of Michigan Health
Ann Arbor, MI

FACULTY_NAME

Christopher King, MD, FCCP

Associate Medical Director, Transplant and Advanced Lung Disease Program
Inova Fairfax Hospital
Associate Clinical Professor of Medicine
Virginia Commonwealth University
Fairfax, VA


Physician Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures of Conflicts of Interest

Kevin Flaherty, MD
  • Consulting: Arrowhead, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, DevPro, Fibrogen, Genentech/Roche, Horizon, Lupin, Pliant, Polarean, Pure Health, Pure Tech, Shionogi, Sun Pharmaceuticals, and United Therapeutics
Christopher King, MD, FCCP
  • Consulting: Actelion, Boehringer Ingelheim Pharmaceuticals, Inc, and United Therapeutics
  • Speakers Bureau: Actelion, Boehringer Ingelheim Pharmaceuticals, Inc, and Genentech

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures
  2. Participate in the online activity
  3. Submit the evaluation form

If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be emailed to you.

If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

For CME questions please contact: info@francefoundation.com.